Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000031594 | SCV000300966 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2016-09-08 | reviewed by expert panel | curation | Variant allele predicted to encode a truncated non-functional protein. |
Consortium of Investigators of Modifiers of BRCA1/2 |
RCV000031594 | SCV000327329 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2015-10-02 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003473196 | SCV004210504 | pathogenic | Familial cancer of breast | 2024-03-04 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000496692 | SCV004438028 | pathogenic | Hereditary breast ovarian cancer syndrome | 2024-03-17 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Glu2004Valfs*34) in the BRCA2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA2 are known to be pathogenic (PMID: 20104584). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with BRCA2-related conditions. ClinVar contains an entry for this variant (Variation ID: 38013). For these reasons, this variant has been classified as Pathogenic. |
Sharing Clinical Reports Project |
RCV000031594 | SCV000054201 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2009-03-04 | no assertion criteria provided | clinical testing | |
Research Molecular Genetics Laboratory, |
RCV000496692 | SCV000587817 | pathogenic | Hereditary breast ovarian cancer syndrome | 2014-01-31 | no assertion criteria provided | research |